Commercially launch its first AI-enabled prostate cancer test
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Nov 2025
- Due
- 30 Jun 2026
- Delivered
- May 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“intends to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026.”
What we found
Evidence strength A What the grades mean
Myriad Genetics launched its first AI-enabled prostate cancer test, Prolaris + AI, in May 2026, which falls within the first half of 2026 deadline.
-
A Myriad Genetics Inc. 10-Q filed 2026-07-31
“In May 2026, we launched Prolaris + AI, the first prostate cancer test to combine” ✓ confirmed on the page
Market reaction: the shares moved -45.0% against the S&P 500 over the three sessions around the disclosure (30 Jul 2026 to 4 Aug 2026). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 3 Nov 2025
Deadline 30 Jun 2026 (“in the first half of 2026”) · wording aspirational
-
Version 2 · stated 23 Feb 2026
Deadline 30 Jun 2026 (“second quarter of 2026”) · wording expected
“full commercial launches of our AI-enabled Prolaris prostate cancer test in partnership with PATHOMIQ expected in the second quarter of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Commercially
- Deliverable
- AI-enabled prostate cancer test
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-MYGN-003943 · Corrections policy